An alternate pathophysiologic paradigm of sepsis and septic shock Implications for optimizing antimicrobial therapy

被引:67
|
作者
Kumar, Anand [1 ]
机构
[1] Hlth Sci Ctr, Sect Crit Care Med, Sect Infect Dis, Winnipeg, MB, Canada
关键词
septic shock; antimicrobial; pharmacokinetics; sepsis; infection; antibiotic; life-threatening infection; combination therapy; survival; STAPHYLOCOCCUS-AUREUS BACTEREMIA; COMBINATION ANTIBIOTIC-THERAPY; CRITICALLY-ILL PATIENTS; BLOOD-STREAM INFECTION; GRAM-NEGATIVE BACTEREMIA; INTENSIVE-CARE-UNIT; PSEUDOMONAS-AERUGINOSA BACTEREMIA; COMMUNITY-ACQUIRED PNEUMONIA; MULTICENTER COLLABORATIVE EVALUATION; VENTILATOR-ASSOCIATED PNEUMONIA;
D O I
10.4161/viru.26913
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The advent of modern antimicrobial therapy following the discovery of penicillin during the 1940s yielded remarkable improvements in case fatality rate of serious infections including septic shock. Since then, pathogens have continuously evolved under selective antimicrobial pressure resulting in a lack of significant improvement in clinical effectiveness in the antimicrobial therapy of septic shock despite ever more broad-spectrum and potent drugs. In addition, although substantial effort and money has been expended on the development novel non-antimicrobial therapies of sepsis in the past 30 years, clinical progress in this regard has been limited. This review explores the possibility that the current pathophysiologic paradigm of septic shock fails to appropriately consider the primacy of the microbial burden of infection as the primary driver of septic organ dysfunction. An alternate paradigm is offered that suggests that has substantial implications for optimizing antimicrobial therapy in septic shock. This model of disease progression suggests the key to significant improvement in the outcome of septic shock may lie, in great part, with improvements in delivery of existing antimicrobials and other anti-infectious strategies. Recognition of the role of delays in administration of antimicrobial therapy in the poor outcomes of septic shock is central to this effort. However, therapeutic strategies that improve the degree of antimicrobial cidality likely also have a crucial role.
引用
收藏
页码:80 / 97
页数:18
相关论文
共 50 条
  • [1] Optimizing Antimicrobial Therapy in Sepsis and Septic Shock
    Kumar, Anand
    [J]. CRITICAL CARE CLINICS, 2009, 25 (04) : 733 - +
  • [2] Optimizing Antimicrobial Therapy in Sepsis and Septic Shock
    Kumar, Anand
    [J]. CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2011, 23 (01) : 79 - +
  • [3] Optimizing Antimicrobial Therapy of Sepsis and Septic Shock Preface
    Kumar, Anand
    [J]. CRITICAL CARE CLINICS, 2011, 27 (01) : XI - XII
  • [4] Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy
    Vazquez-Grande, Gloria
    Kumar, Anand
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (01) : 154 - 166
  • [5] Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
    Liang, Stephen Y.
    Kumar, Anand
    [J]. CURRENT INFECTIOUS DISEASE REPORTS, 2015, 17 (07)
  • [6] Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
    Stephen Y. Liang
    Anand Kumar
    [J]. Current Infectious Disease Reports, 2015, 17
  • [7] Optimal antimicrobial therapy and antimicrobial stewardship in sepsis and septic shock
    Seok, Hyeri
    Park, Dae Won
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2019, 62 (12): : 638 - 644
  • [8] Sepsis and septic shock: Selection of empiric antimicrobial therapy
    Cunha, Burke A.
    [J]. CRITICAL CARE CLINICS, 2008, 24 (02) : 313 - +
  • [9] Early antimicrobial therapy in severe sepsis and septic shock
    Kumar A.
    [J]. Current Infectious Disease Reports, 2010, 12 (5) : 336 - 344
  • [10] Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance
    Strich, Jeffrey R.
    Heil, Emily L.
    Masur, Henry
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2020, 222 : S119 - S131